Condition

Acquired Immunodeficiency Syndrome

ClinicalTrials.gov condition label

Clinical trials152

Recruiting1

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC VirusNCT02479698 · 2015-07-23

Fuyang Jiedu Granules Plus Antiretroviral Therapy for HIV Immune Non-Responders With Spleen-Kidney Yang DeficiencyNCT07698548 · 2026-08-01

NOT_YET_RECRUITING

Qiling Yiqi Tablets Plus Antiretroviral Therapy for HIV Immune Non-responders With Lung-Spleen Qi DeficiencyNCT07698574 · 2026-08-01

NOT_YET_RECRUITING

A Multicenter Prospective Clinical Cohort Study on the Pathogen Spectrum of HIV/AIDS Complicated With InfectionNCT06280001 · 2024-03-01

NOT_YET_RECRUITING

Point of Care Tests to Identify Opportunistic Infections in Advanced HIV Patients in Mexico CityNCT05685641 · 2023-04-01

Managing Hypertension Among People Living With HIVNCT05031819 · 2022-10-26

Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF ToxicityNCT05493969 · 2022-08-01

Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected AdultsNCT04983030 · 2022-04-01

Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in MenNCT04772469 · 2021-03-22

Technological Intervention for Reducing Alcohol Use Among People Living With HIV/AIDSNCT03746600 · 2020-05-23

HIV Indicator Diseases in Hospital and Primary CareNCT05225493 · 2020-01-01

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious DiarrheaNCT04192487 · 2019-10-22

POC Strategies to Improve TB Care in Advanced HIV DiseaseNCT04122404 · 2019-10-14

A Unified Intervention for Young Gay and Bisexual Men's Minority Stress, Mental Health, and HIV RiskNCT02929069 · 2016-09-01

Clinical Trial of Recombinant Adenovirus Type 5 AIDS VaccineNCT02762045 · 2016-04-01

Community Intervention for HIV Testing & Care Linkage Among Young MSM in BulgariaNCT02639754 · 2015-12-01

Accuracy Evaluation of the BD FACS Presto SystemNCT02396355 · 2015-02-01

Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed HAARTNCT02322827 · 2014-11-01

HIV Medication Adherence in Underserved PopulationsNCT02392884 · 2014-09-01

Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.NCT02583464 · 2014-09-01

Peripheral Arterial Insufficiency Associated With HIV/AIDSNCT02264509 · 2014-09-01

DVD-based HIV/HCV Prevention Intervention for Drug-Involved Latino Criminal Justice ClientsNCT02116179 · 2014-07-01

HIV, Buprenorphine, and the Criminal Justice System (STRIDE2)NCT03583138 · 2014-06-23

Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical CancerNCT01590017 · 2014-04-01

Anti-HIV False Positivity Rate in Pregnant Women; and Investigating the Factors Affecting This SituationNCT03777371 · 2014-01-01

Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced AdultsNCT01967940 · 2013-10-25

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive AdultsNCT01968551 · 2013-09-03

Differences in Response to the Flu Vaccine Among Adults With HIV and Without HIV in UgandaNCT01916759 · 2013-06-01

Safety and Immunogenicity of Recombinant HIV Vaccines for HIV/AIDSNCT01881581 · 2013-06-01

Primary Care-Based Interventions to Reduce Alcohol Use Among HIV PatientsNCT01671501 · 2013-03-01

Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TBNCT02348177 · 2013-01-01

Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in AdolescentsNCT01721109 · 2012-12-06

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive WomenNCT01705574 · 2012-10-24

Pilot Study of Immediate HIV Treatment in Guangxi, ChinaNCT01892228 · 2012-07-01

Improving Uptake of Early Infant Diagnosis of HIV for the Prevention of Mother-to-child Transmission of HIVNCT01433185 · 2012-04-01

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive AdultsNCT01565850 · 2012-04-01

HIV, Buprenorphine, and the Criminal Justice SystemNCT01550341 · 2012-02-23

Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in KenyaNCT01425073 · 2012-02-01

Dimiracetam in Painful Neuropathies Affecting AIDS PatientsNCT01444690 · 2012-01-01

Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsNCT01533259 · 2012-01-01

Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive AdultsNCT01497899 · 2011-12-28

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsNCT01495702 · 2011-12-01

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected PatientsNCT01475838 · 2011-11-01

A Commitment Device for Medication Adherence Among HIV PatientsNCT01455740 · 2011-10-01

Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected AdultsNCT01440569 · 2011-09-01

Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal ImpairmentNCT01363011 · 2011-05-01

Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima PeruNCT02630082 · 2011-04-01

Managerial Database IINCT01322217 · 2011-04-01

Stanford Universities: The Stanford HIV Aging CohortNCT01401348 · 2010-12-01

Text Messaging to Improve Adherence to Clinic Visits and Reduce Early Resumption of Sexual Intercourse After Male CircumcisionNCT01186575 · 2010-08-01

Intervention for HIV-Positive Black Young Men Who Have Sex With Men (YMSM)NCT01502618 · 2010-08-01

HAART Adherence Among HIV-infected Persons and the Factors Affecting Treatment AdherenceNCT01369056 · 2010-07-01

Mesalamine to Reduce T Cell Activation in HIV InfectionNCT01090102 · 2010-06-01

Chinese Network of Pediatric Antiretroviral TherapyNCT01210924 · 2010-04-01

Computerized HIV/Sexually Transmitted Disease (STD) Prevention ProgramNCT00947947 · 2010-02-01

Clinic-based ART Diagnostic EvaluationNCT01791556 · 2010-01-26

Intervention of HIV, Drug Use and the Criminal Justice System in MalaysiaNCT02396979 · 2010-01-01

Pilot Assessment of Lopinavir/Ritonavir and MaravirocNCT00981318 · 2009-12-01

Medications for Chronic HIV: Education and CollaborationNCT01038076 · 2009-12-01

An Expanded Safety Study of Dapivirine Gel 4759 in AfricaNCT00917891 · 2009-11-01

Common interventions

Leading sponsors

National Institute of Allergy and Infectious Diseases (NIAID)15 National Heart, Lung, and Blood Institute (NHLBI)13 Gilead Sciences11 National Cancer Institute (NCI)8 Merck Sharp & Dohme LLC6 University of California, San Francisco5 University of Washington5 Boehringer Ingelheim4 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.4 University of North Carolina, Chapel Hill4 Yale University4 National Center for Complementary and Integrative Health (NCCIH)3 National Eye Institute (NEI)3 Beijing University of Chinese Medicine2 Centers for Disease Control and Prevention, China2

Trial status mix

COMPLETED133

UNKNOWN12

NOT_YET_RECRUITING3

TERMINATED2

RECRUITING1

WITHDRAWN1

Phase mix

NA36

PHASE230

PHASE321

PHASE116

PHASE412

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.